not used title

not used title

Unfortunately, policymakers are again looking for bumper-sticker answers to the health care affordability challenges many Americans face, ignoring real commonsense solutions in exchange for flawed government “negotiation” schemes. The current misguided drug pricing plan included in the reconciliation package mandates the government set prices for medicines – a plan that will completely upend our competitive ecosystem in the United States and threaten access to new medicines.

The plan guts the very incentives necessary to encourage investment in research and development, perpetuates existing problems with our current health care system and fails to address the real challenges of inadequate insurance coverage causing patients to struggle to afford their medicines.

I recently had the chance to hear from Stephanie, an arthritis patient and mother from Montana, and Daniel, a young chef who battled COVID-19 and serves as a caregiver to his father with Graham-Stout disease from Arizona. As patients and caretakers, these individuals have an acute understanding of the very real consequences government price setting would have for patients.

+++

Andrew: America is home to the greatest research and development (R&D) ecosystem in the world helping to deliver new treatments and cures to patients. Why is it so critical the United States continues to lead the world in this lifesaving R&D?

Daniel: First and most importantly, my father suffers from a rare and painful condition that causes his bones to deteriorate. My family and I desperately want to see a cure, and I know America’s biopharmaceutical companies help provide our best shot. Second, I work in the food services industry as a chef and need to stay healthy to do my job. I’ve already had to miss numerous weeks of work due to catching COVID-19 on multiple occasions. With new variants seeming to pop up every few months, I could not think of a more important time for our country to prioritize medical research.

Stephanie: As someone with rheumatoid arthritis, it is a constant battle to manage my joint pain, swelling and tenderness. While I am fortunate to have access to prescription medications that help, I am always hopeful for new options that could improve my quality of life even more. I also know that one new medication isn’t going to help all 1.3 million of my fellow arthritis patients here in the United States, so we need robust research that leads to multiple new treatment options.

Andrew: If Congress moves forward with government price-setting proposals and we see less investment in lifesaving biopharmaceutical R&D, we will see a reduction in the number of new cures and treatment options available to American patients. As an American and a patient/caregiver, how does this make you feel?

Daniel: I don’t understand why politicians would want to move forward with any policies that would decrease the number of new cures and treatments available that could help people. Even worse, what if one of the treatments not discovered because of price setting is one that would help my dad? Honestly, it frustrates me.

Stephanie: It’s discouraging. COVID-19 vaccines are a clear example of what can happen when our government supports scientists and researchers and empowers them to do what they do best, which is to innovate. To me, the evidence is clear: we need policies that encourage the creation of new treatments, not policies that disincentivize continued investment.

Andrew: Many believe rather than proceeding with price-setting proposals that jeopardize patient access to lifesaving treatments, Congress should focus on bipartisan solutions that would meaningfully address costs for patients like capping out-of-pocket costs and making sure insurance coverage actually works for patients when they need it most. Do you agree?

Daniel: I couldn't agree more. At the end of the day, Congress needs to bring down costs for patients, but they need to do so in a way that doesn’t leave patients like my dad behind who desperately need help. To me, the most commonsense way to accomplish this is by making sure that insurance companies are appropriately covering costs and capping what our most vulnerable patients are responsible for covering out of their own pocket.

Stephanie: For years now we have seen insurance premiums and deductibles increase right alongside patient out-of-pocket spending. It just doesn’t make sense that Americans pay more every year for coverage yet consistently get less. For the amount of money people spend each month, the least we can do is make sure insurance acts like insurance when we need it most.

Andrew: If you could deliver one message to politicians in Congress who are considering moving forward with government price setting, what would you say?

Daniel: Politicians need to think of families and patients like my dad who are counting on new drug discovery and the hope for future cures. Find a better way to drive down costs that doesn’t harm lifesaving innovation. We all know that new drug discovery saves lives, and I would ask them to keep that in mind.

Stephanie: I would remind them that America is the most innovative country in the world for a reason. I would make sure they know that the only way we are going to discover new treatments and save lives is by supporting science and those who have the ability to create new medications.

Learn more about why government price setting is bad policy and better ways Congress could help patients access and afford their medicines.

Andrew Powaleny

Andrew Powaleny is the Deputy Vice President of Public Affairs at PhRMA, where he leads communications on scientific, regulatory and intellectual property issues, highlighting the biopharmaceutical industry’s efforts in developing innovative medicines and vaccines while promoting an environment that encourages necessary risk-taking. For five years starting in 2019, he launched and led PhRMA’s grassroots initiative, Voters for Cures, bringing patients and caregivers together to advocate for access to medicine and biopharmaceutical innovation. He also co-founded and co-chaired PRIDE Umbrella, a resource group for LGBTQ+ individuals. Prior to joining PhRMA in 2015, Andrew worked as a communications consultant in Washington, D.C., and as Deputy Press Secretary for the U.S. House Committee on Energy and Commerce under Chairman Fred Upton. He holds a degree in public policy and government from Eastern Connecticut State University, with a minor in music. Outside of work, Andrew enjoys exercise, musical theater and mentoring college students through The Fund for American Studies alumni association.

Andrew Powaleny

Author Twitter

Author LinkedIn

New poll: 2 in 3 voters prefer a candidate committed to lowering health insurance premiums

September 18, 2026

What AARP isn’t telling seniors about MFN

August 24, 2026

Policymakers should improve patient access and reject price controls

August 18, 2026

CMS proposal could discourage patient-centered innovation

August 18, 2026

Nearly 1 in 4 patients initially denied access to IRA medicines

August 6, 2026

Voters continue to voice their concerns on government price controls

July 24, 2026

Medicare Part D at 20: Building on a strong foundation

July 23, 2026

Guest Blog: Price controls won’t lower costs when insurers control access

June 25, 2026

MFN could disrupt the affordable medicines patients depend on

June 18, 2026

New “America Cures” ad: U.S. patients get new medicines first

June 15, 2026

Patients speak out: MFN won't address my affordability concerns

June 4, 2026

MFN price controls threaten American jobs and the U.S. economy

May 28, 2026

Ahead of ASCO: Cancer innovation is promising, but policy choices matter

May 26, 2026

State price-setting boards create more questions than answers

May 20, 2026

New analysis highlights access to new medicines in the United States and abroad

May 13, 2026

MFN won’t lower costs when insurers call the shots

May 8, 2026

Guest Blog: How MFN price controls could decide my health care

April 30, 2026

MFN price controls would drain pensions and put retirements at risk 

April 23, 2026

States should avoid repeating the IRA’s price‑setting mistakes 

April 21, 2026

CMS undermines medical progress with MFN price controls 

April 16, 2026

Trump Administration’s efforts to have other countries pay their fair share are underway

April 15, 2026

CMS’ MFN proposals won’t help seniors despite lofty promises

April 9, 2026

Voters voice concerns on government price controls

April 7, 2026

Virginia should be cautious about importing federal price-setting mechanisms

April 1, 2026

Policymakers shouldn’t double down on the IRA’s flaws with MFN

March 30, 2026

MFN drug pricing risks reviving a harmful metric the U.S. rejected

March 16, 2026

Leadership in biopharmaceutical R&D provides U.S. patients the greatest access to innovative medicines

March 11, 2026

Harmful U.S. policies will help drive China’s global leadership in biopharmaceutical innovation

March 4, 2026

MFN undermines U.S. biopharmaceutical innovation

February 25, 2026

CMS puts patients and innovation at risk with MFN

February 24, 2026

New list of selected drugs highlights growing consequences of government price setting

January 28, 2026

Price setting policies put cancer gains in jeopardy

January 16, 2026

Myth vs. Fact: How government price setting impacts innovation

November 24, 2025

The IRA’s price setting doesn’t guarantee lower costs or better access

November 17, 2025

PhRMA calls on USTR to ensure foreign nations pay their fair share

November 4, 2025

What seniors can expect this open enrollment

October 14, 2025

Part D premiums are going up, while choices are going down

October 8, 2025

Why states struggle to deliver savings: Middlemen and 340B siphon dollars from patients and states

September 15, 2025

Celebrating 60 Years of Medicare

July 30, 2025

Medicare patients face higher drug costs, despite IRA promises

July 22, 2025

CMS continues to make a bad law worse

June 27, 2025

ICYMI: Forget Foreign Price Controls: There’s a better solution to lowering drug prices

June 26, 2025

Americans are paying a 26% freerider tax on medicines because other countries don’t pay their fair share

June 17, 2025

New “Balance the Scales” campaign highlights why Americans pay more for prescription medicines

May 21, 2025

Foreign first pricing schemes don’t address why Americans pay more

May 15, 2025

New analysis: Fewer treatments and cures under the IRA’s pill penalty

May 1, 2025

How the IRA is impacting the generic drug market

April 8, 2025

Three reasons Congress should fix the IRA’s pill penalty

March 24, 2025

Improved treatments continue to lead to declining cancer mortality rates in the U.S.

February 25, 2025

Biopharmaceutical innovation for a healthier America: PhRMA releases new innovation report

February 21, 2025

New policy agenda charts solutions for a healthier America

February 20, 2025

A successful PhRMA Forum highlights our commitment to a healthier America

February 20, 2025

Guest Perspective: Prioritize Innovative Care

February 11, 2025

Virginia, Don't Let Politicians Take Away Your Medicine

January 23, 2025

Patients are losing as government price setting continues

January 17, 2025

PhRMA CEOs Tee Up Next Week's Health Care Conference

January 11, 2025

Post-approval R&D is critical for fighting cancer. The IRA makes it more difficult.

November 13, 2024

Reimagining patient access through meaningful policy reform

November 5, 2024

CMS needs to do better

November 4, 2024

Guest Post: My health care vote

October 29, 2024

The Patient Perspective: Vaccines

October 23, 2024

Is CMS paying attention to the growing access barriers for Medicare patients under the IRA?

October 18, 2024

7 reasons why states shouldn’t copy the IRA’s price setting mistake

October 15, 2024

Did the administration consider the importance of blood cancer medicines to patients in price setting process?

October 8, 2024

Did the administration consider the importance of blood clot medicines to patients in the price setting process?

September 25, 2024

Three ways state drug price setting boards fail patients

September 18, 2024

The Inflation Reduction Act could increase costs and reduce access for millions of seniors

September 17, 2024

Are the IRA’s Part B inflation rebates lowering costs for Medicare patients? No.

September 16, 2024

Did the administration consider the importance of autoimmune disease medicines to patients in price setting process?

September 11, 2024

Patient priorities in the 2024 election

September 10, 2024

Did the administration consider the value of innovative diabetes medicines in price setting process?

August 28, 2024

New survey: Insurers confirm IRA will reduce patient treatment options

August 20, 2024

The unintended consequences of government price setting in Medicare Part D

August 16, 2024

Don’t put the government between patients and their medicines

August 7, 2024

Biosimilars continue to drive market competition and increase savings for seniors

August 6, 2024

What is the low-income subsidy program and how is it changing?

July 31, 2024

Case study: How seniors could face access disruptions because of the IRA’s price setting provisions

July 22, 2024

WTAS: Voters voice concerns about PBM abuses, call on policymakers to act

July 19, 2024

PhRMA reiterates concerns with IRA price setting program, urges CMS to mitigate harm

July 3, 2024

More than 60 researchers advocate on Capitol Hill

July 1, 2024

The IRA could lead to higher out-of-pocket costs for 3.5 million Medicare patients in 2026

June 25, 2024

ICYMI: What patients care about this election year

June 24, 2024

ICYMI: Health care policy should be driven by patients, not politics

June 10, 2024

ICYMI: Misaligned policies undermine patient access

June 6, 2024

ICYMI: Innovation transforms lives but misguided federal policies threaten patient outcomes

May 30, 2024

How the IRA is more coercive than any European government price setting scheme

May 29, 2024

Mental Health Awareness Month: Supporting loved ones and improving mental health in America

May 28, 2024

How government price setting fails to address systemic health care inequities

May 24, 2024

Government price-setting boards: Why Minnesota needs to take a better approach

May 9, 2024

IRA is already negatively impacting access to medicines in Part D

April 25, 2024

Government price setting won’t help patients in Illinois

April 22, 2024

ICYMI: Voter priorities this election season

April 18, 2024

New analysis: Flawed assessments of a medicine’s value jeopardize patient access

April 11, 2024

3 Takeaways from POLITICO’s Health Care Summit

April 3, 2024

ICYMI: More evidence of the IRA’s harmful consequences on post-approval research and development

March 25, 2024

Colorado is proof: Too many unanswered questions remain about state government price setting's impact on patients and providers

March 14, 2024

Watch: A conversation with Dr. Mike Ybarra on Rare Disease Day

February 29, 2024

American Heart Month: A nurse’s perspective

February 27, 2024

The truth about Nebraska's price setting push

February 13, 2024

Four years later, Maryland board still hasn’t delivered for patients

February 12, 2024

Setting the Record Straight: Comparing U.S. drug prices to those in foreign countries hurts patients

February 7, 2024

As the administration continues to falsely claim Medicare “negotiation,” keep these points in mind

February 1, 2024

Powering the next generation of therapies: A conversation with Astellas US President Mark Reisenauer

January 30, 2024

When it comes to the future of innovation, the ball is in policymakers’ court

January 22, 2024

Biosimilars drive savings, but the IRA undermines their development

December 14, 2023

New analysis of patient access restrictions in the United Kingdom

November 21, 2023

The IRA’s pill penalty threatens the future of oncology R&D

November 16, 2023

ICYMI: WSJ — Same Drug, Two Prices: Why the Higher Price Prevails

November 15, 2023

Don't close the door on rare disease research

November 13, 2023

ICYMI: 3 takeaways on the IRA’s unintended consequences from America’s Physician Groups’ 2023 annual fall conference

November 6, 2023

ICYMI: Scott LaGanga and Matt Salo deliver a State of the Industry Report

October 25, 2023

R&D leaders to Biden Administration: Your policies are undermining the Cancer Moonshot

October 18, 2023

Three things economists are saying about the Inflation Reduction Act

October 11, 2023

4 truths about state government price setting

October 10, 2023

Word of the Month: AMR

September 27, 2023

IRA threatens seniors’ access to robust treatment options

September 26, 2023

New analysis shows PBMs use fees as a profit center

September 18, 2023

Correcting the record: IRA’s government price setting provisions are unconstitutional

September 8, 2023

New PhRMA ad exposes yet another way PBMs get between patients and their medicines

September 5, 2023

IRA changes to Part D risk access to medicines

August 24, 2023

Three concerns about Colorado's approach to government price setting

August 23, 2023

With the first list of medicines out, let’s not forget why government price setting is bad policy

August 22, 2023

Michigan proposal jeopardizes access to medicines

August 21, 2023

One year later IRAs unintended consequences are becoming reality

August 16, 2023

AARP’s latest misleading report

August 11, 2023

Navigating the Patient Experience Survey: Protecting Lifelines to Access and Innovation

July 26, 2023

New report shows high-impact R&D happens after cancer medicines are first approved

July 10, 2023

More than 60 researchers ask Congress to support innovation

June 26, 2023

New report shows how the Inflation Reduction Act stifles innovation for small molecule medicines

June 22, 2023

ASCO 2023: Protecting our progress in the fight against cancer

June 15, 2023

Highlights from ASCO 2023

June 8, 2023

Four things for CMS to keep in mind as they implement changes to Part D

June 7, 2023

Addressing Mental Health: A conversation with Barry Greene, CEO of Sage Therapeutics

May 30, 2023

Mental Health Awareness Month: Fighting the growing mental health crisis and supporting innovation

May 11, 2023

4 key facts on medicine prices and spending

May 9, 2023

Support for continued progress is critical for pediatric drug development

May 8, 2023

New resource underscores the importance of small molecule medicines

May 4, 2023

Americans want state policymakers to lower out-of-pocket costs

May 1, 2023

Policies need to address the growing threat of antimicrobial resistance

April 28, 2023

Three facts about health care spending

April 25, 2023

AHIP’s latest misinformation campaign & what it’s trying to hide

April 24, 2023

CMS guidance on IRA price setting process doubles down on bad policy

April 14, 2023

New global analysis shows patient access challenges around the world

April 12, 2023

ICYMI: PhRMA President and CEO Stephen J. Ubl discusses patient affordability

April 7, 2023

States can support access to medicine as COVID-19 Public Health Emergency ends

April 5, 2023

Arkansas puts patients first with new share the savings law

April 4, 2023

New Report: More than 400 medicines in development for leading chronic conditions affecting older Americans

March 28, 2023

Celebrating the success of the COVID-19 vaccines, and looking to the future

March 27, 2023

IRA Impacts: Cancer treatment research and development

March 23, 2023

Celebrating 40 years of the Orphan Drug Act on Rare Disease Day

February 28, 2023

Holding pharmacy benefit managers accountable

February 23, 2023

Stopping pharmacy benefit managers from “gaming the system”

February 22, 2023

Recognizing National Glaucoma Awareness Month

February 1, 2023

ICYMI: PhRMA kicks off the year at the 2023 J.P. Morgan Health Care Conference

January 19, 2023

WTAS: Inflation Reduction Act already impacting R&D decisions

January 17, 2023

In their own words: Insured Americans support policy reforms that address access and affordability concerns

December 14, 2022

ICYMI: PhRMA COO Lori Reilly speaks about the health care agenda for the next Congress

December 9, 2022

New government price setting policy threatens post-approval research

November 10, 2022

A key fact the White House is reluctant to admit

September 27, 2022

A key fact the White House is reluctant to admit

September 27, 2022

Navigating the patient experience: Burdens and barriers standing between patients and their care

September 12, 2022

Rejecting ICER’s bad advice

September 9, 2022

New survey: Voters seriously concerned about fine print in reconciliation bill

August 12, 2022

This week’s reading list: All the reasons the Senate-passed drug pricing bill is bad policy

August 10, 2022

Myth vs. Fact: The Senate’s latest price setting proposal

August 5, 2022

An open letter to Congress: Stand with patients and future cures

August 4, 2022

ICYMI: Patients across the country are sharing concerns about government price setting

August 3, 2022

The Senate’s latest price setting proposal will undermine U.S. economic growth

August 3, 2022

Celebrating Medicare’s 57th anniversary

August 2, 2022

New analysis finds deeper impact of drug pricing bill on biopharmaceutical researchers

August 1, 2022

ICYMI: A patient, physician, biotech investor and industry leaders warn about the dangers of government price setting bill

July 29, 2022

The Senate’s latest price setting proposal will undermine: Our health care system

July 28, 2022

The Senate’s latest price setting proposal will undermine: American medical innovation

July 27, 2022

The Senate’s latest price setting proposal will undermine: Patient access to medicines

July 26, 2022

Putting patients first at the state level — A conversation with Mark Reisenauer, President of Astellas Pharma US

July 14, 2022

Polling continues to show voters reject so-called Medicare “negotiation” once they learn about consequences for patients

July 12, 2022

By the Numbers: Patients lose when the government sets prices

July 8, 2022

Patients win as West Virginia implements first-in-nation share the savings policy

July 8, 2022

Spotlighting a growing mental health challenge

May 9, 2022

Three charts show how the Medicare Part D program could be improved to work better for seniors and people with disabilities

April 27, 2022

Analysis: States can help patients save nearly $1,000 annually on their medicines

April 21, 2022

Guest Post: If we truly want to cure complex diseases, politicians should reject price setting

March 14, 2022

Veterans Affairs 101: Three charts show how the VA system differs from Medicare

March 11, 2022

Government price setting leaves behind families counting on new medicines

February 23, 2022

PhRMA submits comments urging CMS to withdraw coverage proposal

February 11, 2022

Medicaid 101: Three charts on access and spending

February 3, 2022

Government price setting won’t stop insurers from shifting costs to patients

February 2, 2022

New comments outline ways to counteract cost-shifting insurance trends

January 28, 2022

It’s a new year, but sadly Congress is still pursuing flawed price setting policies

January 25, 2022

New study finds more than half of brand medicine spending goes to the supply chain and others

January 7, 2022

Making medicines more affordable: Preserving safety-net programs like 340B

December 17, 2021

Post-approval research save lives. Why is Congress trying disincentivize it?

December 17, 2021

A price control by any other name would still put patients at risk and threaten innovation

December 9, 2021

Making medicines more affordable: Making insurance work like insurance

December 8, 2021

Navigating the patient experience in the time of COVID-19

December 6, 2021

Guest post: Congress should not put future innovation at risk

November 29, 2021